In the intricate landscape of glycomics, the ability to selectively modify complex carbohydrates is a prerequisite for therapeutic innovation. CD BioGlyco offers an elite enzyme-catalysis-based glycan modification service, representing a sophisticated vertical within our synthetic biology-based platform. Unlike traditional chemical synthesis, which often struggles with the stereochemical complexity and regional similarity of hydroxyl groups, enzymatic catalysis utilizes millions of years of evolutionary precision. Our platform harnesses highly specific carbohydrate-active enzymes (CAZymes) to perform site-specific glycosylation, sulfation, and epimerization under mild, aqueous conditions. By integrating recombinant protein engineering with advanced glyco-analytics, we provide a "green" and high-fidelity pathway for the remodeling of carbohydrate antigens and Human Milk Oligosaccharides (HMOs), enabling the development of next-generation biologics and glycomimetic drugs.
Core Technologies
Engineered Glycosynthases
We employ modified glycosidases where the catalytic nucleophile is replaced, preventing product hydrolysis and allowing for the high-yield assembly of oligosaccharides using activated donors.
Multi-Enzyme One-Pot (OPME) Systems
Sophisticated cascades that combine sugar nucleotide regeneration with glycosyltransferase reactions, minimizing substrate inhibition and reducing the cost of expensive sugar donors.
Site-Specific Glycan Remodeling
Utilizing endoglycosidases (such as Endo-S or Endo-M variants) to trim heterogeneous glycans from antibodies or proteins, followed by the enzymatic attachment of a defined, homogeneous glycan structure.
Directed Evolution of CAZymes
Utilizing high-throughput screening to evolve enzymes with non-natural substrate specificity, improved thermal stability, or enhanced activity in organic co-solvents.
Chemoenzymatic "Stop-and-Go" Strategy
A hybrid approach where chemical synthesis provides modified sugar building blocks that are then enzymatically incorporated into complex glycan chains with absolute regioselectivity.
Orchestrating Molecular Precision through Nature's Own Catalysts.
Our service scope is vast, catering to the most demanding requirements of the biopharmaceutical and diagnostic industries. We specialize in the enzymatic synthesis of complex N-glycans and O-glycans, providing researchers with well-defined structures that are otherwise impossible to isolate from natural sources. This includes the production of highly sialylated and fucosylated oligosaccharides, which are critical for modulating the half-life and immunogenicity of therapeutic glycoproteins.
We provide a dedicated service for antibody glyco-remodeling, where we utilize specialized enzymes to homogenize the Fc-glycan profile of IgG molecules. This process is essential for enhancing antibody-dependent cellular cytotoxicity (ADCC) and ensuring therapeutic efficacy. Furthermore, we offer the enzymatic modification of glycosaminoglycans (GAGs), such as heparan sulfate, where we introduce specific sulfation patterns that govern growth factor binding and cellular signaling. Our scope also encompasses the synthesis of non-natural glycan analogs containing bio-orthogonal handles (e.g., azides or alkynes), allowing for downstream "click" chemistry applications in cellular imaging. With capabilities ranging from milligram-scale modification for lead discovery to multi-gram production for preclinical evaluation, we handle the complete lifecycle of enzymatic glycan tailoring. We also provide donor substrate synthesis, ensuring a steady supply of UDP-sugars, GDP-sugars, and CMP-sialic acid required for large-scale biocatalysis. By eliminating the need for toxic catalysts and complex protecting group strategies, our service offers a streamlined, sustainable, and scientifically superior alternative to traditional glycan modification.
Workflow
Substrate Assessment & Enzyme Selection
We analyze your starting material (protein, peptide, or small molecule glycan) and screen our vast internal library of glycosyltransferases, sulfotransferases, and epimerases for the optimal catalytic match.
Cascade Design & Optimization
Our scientists design an enzymatic pathway that manages donor regeneration and byproduct removal (e.g., phosphatase treatment to remove inhibitory inorganic phosphates), ensuring high conversion rates.
Biocatalytic Transformation
The reaction is conducted in controlled bioreactors where parameters such as pH, temperature, and metal ion cofactors are strictly maintained to maximize enzyme longevity and regioselectivity.
In-Process Monitoring
Real-time analysis using LC-MS or HPLC allows us to track the disappearance of substrates and the emergence of the modified glycan, preventing over-reaction or glycan degradation.
Downstream Purification
Enzymes and sugar nucleotides are removed via specialized filtration, ion-exchange, or size-exclusion chromatography to isolate the modified glycan product with >95% purity.
Structural Confirmation
We utilize high-resolution mass spectrometry (HRMS) and 1D/2D NMR to provide a definitive "fingerprint" of the modified glycan, ensuring the linkage and position are exactly as specified.
Publication Data
Journal: ACS catalysis
DOI: 10.1038/am.2017.241
Published: 2022
IF: 3.9
Results: This perspective article provides a comprehensive overview of the field of site-selective modification of (oligo)saccharides, highlighting it as a key strategy for studying carbohydrate function and developing therapeutic agents like drugs and vaccines. The authors discuss the significant progress driven by diverse catalytic approaches, including transition-metal catalysis, organocatalysis, and particularly photoredox catalysis, which enables the discrimination and modification of specific hydroxy groups in unprotected or minimally protected sugars. They review applications such as the synthesis of rare sugars and the installation of chemical handles for biological probes, while also addressing the greater challenge of selectively modifying one residue within complex oligosaccharides and glycans. The article concludes that while the chemical and enzymatic modification fields are advancing towards the same goal, their eventual convergence holds great promise for fundamentally advancing glycochemistry and its biomedical applications.
Applications
Therapeutic Protein Engineering
By intentionally modifying the glycan structures attached to cytokines, hormones, and enzymes, it is possible to enhance their metabolic stability and reduce clearance by the host immune system. These glycan profile alterations can prolong circulation time, improve bioavailability, and increase therapeutic efficacy.
Antibody Optimization
The effector functions of therapeutic antibodies, such as antibody-dependent cellular cytotoxicity (ADCC), can be enhanced through targeted glycoengineering. This includes enzymatic removal of core fucose or the addition of terminal galactose residues, which improve antibody binding to immune effector cells and fine-tune immune activation.
Glycan-Based Vaccine Development
This involves the design and synthesis of well-defined tumor-associated carbohydrate antigens (TACAs) and viral glycan decoys for use in vaccine formulations. These glycoconjugates can elicit highly specific and potent immune responses, offering promising strategies for cancer immunotherapy and antiviral protection.
Glyco-Biomarker Standard Development
To improve reproducibility and accuracy in clinical diagnostics, isomerically pure glycan standards are being produced. These standards enable precise calibration of mass spectrometry instruments and immunoassays, facilitating reliable detection and quantification of glycan biomarkers in patient samples.
Advantages
Absolute Regioselectivity
Our enzymatic platform achieves precise control over glycosylation sites, enabling it to distinguish between chemically identical hydroxyl groups on a single sugar ring. This high-fidelity specificity eliminates the formation of unwanted positional isomers, a common and costly challenge in conventional chemical synthesis, ensuring the production of structurally defined glycans with exceptional purity.
Stereochemical Perfection
Leveraging the inherent precision of biocatalysis, our system guarantees the formation of 100% pure α- or β-glycosidic linkages. This eliminates anomeric mixtures that can compromise biological activity, ensuring that the functional integrity and efficacy of the synthesized glycan or glycoconjugate are fully preserved.
Mild Reaction Conditions
Our platform operates under gentle, biocompatible conditions, near-neutral pH and ambient temperatures. This makes it particularly suitable for modifying sensitive biomolecules such as proteins, peptides, or functionalized glycans that might denature, degrade, or lose activity under the harsh conditions typically required for chemical synthesis.
Elimination of Toxic Metals
By employing enzyme-based catalysis, our process completely avoids the use of heavy metals and other toxic reagents common in traditional synthetic chemistry. This results in cleaner product profiles, simplifies downstream purification, and yields glycans that are inherently safer for therapeutic, diagnostic, and clinical applications.
Frequently Asked Questions
Customer Review
"The glyco-remodeling of our lead antibody by CD BioGlyco was flawless. The homogeneity of the G0F profile was exactly what we needed for our ADCC assays."
– Dr. A.L., Senior Scientist, Biologics Development
"We saved six months of work by choosing CD BioGlyco's enzymatic modification service over our internal chemical synthesis route. The regioselectivity was 100%."
– Manager, Glycochemistry Research
"The purity of the synthetic TACAs provided by CD BioGlyco allowed us to move into animal trials with high confidence. Their structural verification is top-tier."
– Dr. B.W., Head of Vaccine Development
Associated Services
Our enzyme-catalysis-based glycan modification service leverages the precision of enzymatic methods, such as the use of specific glycosyltransferases and nucleoside-activated glycosyl donors for controlled glycosidic bond formation, to achieve highly specific modifications on carbohydrate structures. Building upon this core expertise in enzyme-driven synthesis, we apply these precise biocatalytic strategies to the scalable production of well-defined immunologically relevant molecules. This capability is integral to our Carbohydrate Antigen Production Service, which includes the synthesis of the blood group B tri-saccharide antigen (an erythrocyte phenotypic antigen that effectively stimulates antibody production), the blood group A hexa-saccharide antigen (which elicits a homotypic immune response), and the blood group B hexa-saccharide antigen (a key human erythrocyte surface antigen) for applications in diagnostics and immunology research.
Blood Group B Tri-saccharide Antigen
Blood Group A Hexa-saccharide Antigen
Blood Group B Hexa-saccharide Antigen
CD BioGlyco is the partner of choice for companies looking to lead the next wave of microbiome innovation. Contact us to learn more about our service that provides the biological precision required to turn probiotics into powerful, targeted therapeutic tools.
Reference
Witte, M.D.; Minnaard, A.J. Site-selective modification of (oligo) saccharides. ACS catalysis. 2022, 12(19): 12195-12205. (Open Access)
For research use only. Not intended for any clinical use.
